Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention

CompletedOBSERVATIONAL
Enrollment

1,505

Participants

Timeline

Start Date

July 20, 2021

Primary Completion Date

August 5, 2021

Study Completion Date

August 6, 2021

Conditions
Platelet Aggregation InhibitorsDual Anti-Platelet TherapyAgedPercutaneous Coronary Intervention
Interventions
DRUG

Ticagrelor

Patients were survivors and treated with DAPT (aspirin \[100 mg once daily\], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist \[clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)\]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.

Trial Locations (1)

116011

The First Affiliated Hospital of Dalian Medical University, Dalian

All Listed Sponsors
lead

The First Affiliated Hospital of Dalian Medical University

OTHER

NCT04999293 - Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention | Biotech Hunter | Biotech Hunter